Skip to content
TrialScanner

NCT01995058

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2TerminatedEXELLead

Registry record

Lead sponsor
Exelixis
Conditions
Prostate Cancer; Castration Resistant Prostate Cancer; Prostatic Neoplasms
Primary completion
Nov 2014Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01995058 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.